Phase 3
N=19
Implications of Fecal Microbiota Transplantation in Modulating the Effects of Liver Cirrhosis
Liver Cirrhosis
Bottom Line
View on ClinicalTrials.gov: NCT06478602 ↗Enrolled (actual)
19
Serious AEs
0.0%
Results posted
Mar 2026
Primary outcome: Primary: Liver Stiffness by Transient Elastography (FibroScan) — 22.6; 23 kPa
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Fecal microbiota transplantation (Biological)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Cristian Ichim
- Primary completion
- Dec 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Liver Stiffness by Transient Elastography (FibroScan) |
22.6; 23 | — |
| PRIMARY Implications of Fecal Microbiota Transplantation in Modulating Hepatic Encephalopathy |
5; 3; 1; 7; 0; 3 | — |
Summary
The study aims to investigate the beneficial effects of fecal transplantation in patients diagnosed with liver cirrhosis (regardless of etiology).
Eligibility Criteria
Inclusion Criteria
- Diagnosis of liver cirrhosis according to current protocols.
- Conscious and cooperative adult patients.
Exclusion Criteria
- Patients with hemodynamic and/or respiratory instability.
- Patients with contraindications for colonoscopy or fecal transplantation.
- Patients with acute or chronic infections with HIV, Tuberculosis, MDR Enterobacteria, CMV, parasites, fungi.
- Associated oncological pathology.
- Patients with other causes of severe immunodeficiencies.
- Lack of compliance with the conditions imposed by the research project.
- Patients who do not sign the informed consent.
Data sourced from ClinicalTrials.gov (NCT06478602). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.